文献速递前列腺癌男科与性医学

国际注册研究:前列腺癌根治性治疗后的性功能结局

Sexual function after prostate cancer surgery or radiotherapy in an international registry.
PubMed 文献 · BJU Int · 2026-08-26

基于TrueNTH全球注册的前瞻性队列研究纳入13 413例局限或局部晚期前列腺癌男性,比较根治性前列腺切除(RP)、外照射放疗(EBRT)±雄激素剥夺治疗(ADT)或近距离放疗(BT)后基线至12个月的EPIC-26性功能域评分(SFDS)。所有治疗方式均与性功能显著下降相关,RP的SFDS中位下降最大(-60.0%),BT最小(-40.2%);12个月时63.6%-91.8%患者报告勃起功能差或缺失,RP和EBRT+ADT后最高。

要点

  • 所有根治性治疗均与性功能显著下降相关,RP下降最大(中位SFDS -60.0%)。
  • 12个月时63.6%-91.8%患者报告勃起功能差或缺失,RP和EBRT+ADT后最高。
  • 性辅助器具使用在治疗后增加但总体仍低,应加强治疗前咨询和性康复。

核心结论

  • 所有根治性前列腺癌治疗均与性功能显著恶化相关,支持加强治疗前咨询并将主动管理和结构化性康复早期整合到生存期照护中。

研究设计与样本

  • 前瞻性注册队列研究,分析TrueNTH全球注册中局限或局部晚期前列腺癌男性,纳入有基线及12个月患者报告结局者,共13 413例(RP 85.2%、EBRT only 9.1%、EBRT+ADT 4.3%、BT 1.3%)。

主要发现

  • 所有治疗方式的SFDS均显著下降,RP中位下降最大(-60.0%),BT最小(-40.2%)。
  • 12个月时63.6%-91.8%患者报告勃起功能差或缺失,RP和EBRT+ADT后最高。
  • 性辅助器具使用在治疗后增加但总体仍低。

关键数值与推荐

  • 性功能采用EPIC-26性功能域评分(SFDS)评估,比较基线与12个月评分。
  • 线性回归调整年龄、NCCN风险组、基线SFDS和神经保留意图,用于识别术后12个月SFDS预测因素。

临床怎么用

  • 治疗前应充分告知患者各治疗方式对性功能的显著影响,RP下降最大。
  • 术后应早期整合主动管理和结构化性康复,并关注性辅助器具使用。

局限性

  • 回顾性设计及国际注册中非代表性站点,存在未测量混杂和治疗选择跨国异质性,结果应解释为关联而非因果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Our objective was to evaluate patient-reported sexual function (SF) outcomes and sexual aid use 12 months after curative treatment for prostate cancer (PC). PATIENTS & METHODS: This prospective registry-based cohort study analysed men with localized or locally advanced PC enrolled in the TrueNTH Global Registry. Patients with baseline and 12-month patient-reported outcome measures after radical prostatectomy (RP), external beam radiotherapy (EBRT) ± androgen-deprivation therapy (ADT), or brachytherapy (BT) were included. SF was assessed using the EPIC-26 sexual function domain score (SFDS). Baseline and 12-month EPIC-26 SFDS were compared by treatment group, with additional analyses among RP patients examining outcomes by intent to nerve spare and sexual aid use. Linear regression, adjusted for age, National Comprehensive Cancer Network risk group, baseline SFDS, and intent to nerve spare was used to identify predictors of 12-month SFDS among surgery patients. RESULTS: Overall, 13 413 men were analysed (RP 85.2%, EBRT only 9.1%, EBRT+ADT 4.3%, BT 1.3%). SF declined significantly across all modalities. Median SFDS reduction was greatest after RP (-60.0%) and smallest after BT (-40.2%). At 12 months, poor or absent erectile function was reported by 63.6-91.8% of patients, highest after RP and EBRT+ADT. Sexual aid use increased after treatment but remained low overall. Given the retrospective design and non-representative sites in an international registry setting, these findings should be interpreted as associational rather than causal because of the potential for unmeasured confounding and cross-country heterogeneity in treatment selection. CONCLUSION: All curative PC treatments were associated with substantial deterioration in SF. These findings support enhanced pre-treatment counselling and early integration of proactive management and structured sexual rehabilitation into survivorship care.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Hess-Busch Y, Darr C, Püllen L, et al. Sexual function after prostate cancer surgery or radiotherapy in an international registry. BJU Int. 2026. PMID: 42644433. doi:10.1111/bju.70431

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。